drugset / Trial / NCT05016206
A Study of the Cardiac Effects of Danicopan in Healthy Adults
Phase 1
Completed
33 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
This was a randomized, double-blind, double-dummy, placebo- and positive-controlled, 2-arm (Treatment Arm and Control Arm), parallel study to evaluate the effect of ACH-0144471 (danicopan) on the QT interval in healthy adult participants.
Timeline
- Start
- 2018-07-26
- Primary completion
- 2018-10-12
- Completion
- 2018-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danicopan | Small molecule | 400 mg | Oral |
| Subject | Danicopan | Small molecule | 800 mg | Oral |
| Subject | Danicopan | Small molecule | 1200 mg | Oral |
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.